Takara Bio Inc. (TKBIF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Takara Bio Inc. (TKBIF) trades at $7.30 with AI Score 46/100 (Grade C). Takara Bio Inc. operates in the bioindustry, CDMO, and gene therapy sectors, providing reagents, instruments, and contract services globally. Market cap: $879M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for TKBIF: TKBIF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates TKBIF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
TKBIF: the 2 scored disciplines are evenly split. Dominant signal: Ray Dalio bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Takara Bio Inc. (TKBIF) Healthcare & Pipeline Overview
Takara Bio Inc. is a biotechnology company specializing in reagents, instruments, and contract development and manufacturing services for the bioindustry, CDMO, and gene therapy sectors. With a global presence, the company focuses on regenerative medicine and gene therapy, leveraging its TaKaRa, Clontech, and Cellartis brands to serve research and clinical markets.
What Is the Investment Thesis for TKBIF?
Takara Bio Inc. presents a mixed investment case. The company's strong presence in the regenerative medicine and gene therapy sectors, coupled with its CDMO capabilities, positions it to capitalize on the growing demand for these services. The company's gross margin of 54.0% indicates pricing power and efficient operations. However, the company's negative P/E ratio of -19.17 and a negative profit margin of -16.3% raise concerns about profitability. Upcoming advancements in gene therapy and expansion of CDMO services could serve as catalysts for growth. Investors should monitor the company's ability to improve profitability and manage operational costs.
Based on FMP financials and quantitative analysis
TKBIF Key Highlights
Takara Bio operates in the bioindustry, CDMO, and gene therapy sectors.
- The company has a gross margin of 54.0%, indicating strong pricing power.
- Takara Bio's market capitalization is $0.88 billion.
- The company offers a dividend yield of 1.48%.
- Takara Bio has a beta of 0.36, suggesting lower volatility compared to the market.
Who Are TKBIF's Competitors?
TKBIF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ASPHF Ascentage Pharma Group International | $4.53 | +0.00% | $1.69B | 51 |
| BIESF Biotest AG | $32.00 | +0.00% | $1.60B | 48 |
| DUTV Digital Utilities Ventures, Inc. | $0.55 | +3.46% | $1.91B | — |
| GALNF Galenica AG | $115.00 | +0.00% | $5.73B | 46 |
| TBPH Theravance Biopharma, Inc. | $16.95 | -0.24% | $878M | 95 |
| ALBO Albireo Pharma, Inc. | $44.15 | +0.00% | $916M | 71 |
| RIGL Rigel Pharmaceuticals, Inc. | $45.09 | -3.97% | $834M | 84 |
| ABUS Arbutus Biopharma Corporation | $4.77 | -4.22% | $942M | 83 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are TKBIF's Key Strengths?
Strong presence in the regenerative medicine and gene therapy sectors.
- Established brand reputation with TaKaRa, Clontech, and Cellartis brands.
- Comprehensive CDMO capabilities for biologics development.
- Global presence with operations in key markets.
What Are TKBIF's Weaknesses?
Negative P/E ratio and profit margin raise concerns about profitability.
- Dependence on research and development activities for new product innovation.
- Exposure to regulatory risks and compliance requirements in the healthcare industry.
- Competition from larger and more established biotechnology companies.
What Could Drive TKBIF Stock Higher?
Advancements in gene therapy research and development.
- Expansion of CDMO services to meet growing demand.
- Strategic partnerships with pharmaceutical companies and research institutions.
What Are the Key Risks for TKBIF?
Negative return on equity (-9.2%) — the business is not currently generating profit on shareholder capital.
- Inconsistent delivery — missed Wall Street EPS estimates in 6 of the last 8 reported quarters.
- Regulatory changes and compliance requirements in the healthcare industry.
- Intense competition from other biotechnology companies.
- Economic downturns and market volatility.
- Patent expirations and intellectual property disputes.
- Negative profitability metrics (P/E and Profit Margin).
What Are the Growth Opportunities for TKBIF?
- Expansion of CDMO Services: Takara Bio can expand its contract development and manufacturing organization (CDMO) services to capitalize on the increasing demand for outsourced manufacturing of biologics and gene therapies. The global CDMO market is projected to reach $200 billion by 2030. By investing in additional manufacturing capacity and expanding its service offerings, Takara Bio can attract more clients and increase its revenue stream. Timeline: Ongoing.
- Advancements in Gene Therapy: Takara Bio's focus on developing platform technology for biologics development in gene therapy positions it to benefit from the growing adoption of gene therapies for various diseases. The gene therapy market is expected to reach $36 billion by 2030. Successful development and commercialization of new gene therapies could significantly boost Takara Bio's revenue and market share. Timeline: Ongoing.
- Geographic Expansion: Takara Bio can expand its presence in key markets such as the United States and Europe to capitalize on the growing demand for its products and services. The global biotechnology market is increasingly competitive, and establishing a stronger foothold in these regions can enhance the company's long-term growth prospects. Timeline: Ongoing.
- Strategic Partnerships: Takara Bio can form strategic partnerships with pharmaceutical companies and research institutions to accelerate the development and commercialization of its products and services. Collaborations can provide access to new technologies, funding, and market channels, enhancing the company's competitive position. Timeline: Ongoing.
- Coronavirus Testing Products: Takara Bio can leverage its existing coronavirus testing products to address the ongoing need for diagnostic solutions. The demand for COVID-19 testing remains significant, and the company can continue to innovate and expand its product offerings to capture a larger share of the market. Timeline: Ongoing.
What Are TKBIF's Competitive Advantages?
- Proprietary Technologies: Takara Bio has developed proprietary technologies in gene therapy and regenerative medicine, providing a competitive edge.
- Established Brand Reputation: The company's TaKaRa, Clontech, and Cellartis brands are well-recognized and respected in the biotechnology industry.
- CDMO Capabilities: Takara Bio's contract development and manufacturing organization (CDMO) capabilities provide a barrier to entry for new competitors.
- Global Presence: The company's global presence and established distribution network provide a competitive advantage.
What Does TKBIF Do?
Takara Bio Inc., established in 2002 and headquartered in Kusatsu, Japan, is a biotechnology company operating across the bioindustry, contract development and manufacturing organization (CDMO), and gene therapy sectors. As a subsidiary of Takara Holdings Inc., the company has expanded its reach globally, serving markets in Japan, China, the rest of Asia, the United States, and Europe. Takara Bio offers a diverse portfolio of products and services, including reagents and instruments for genetic research, coronavirus testing kits, analytical reagents, single-cell analysis systems, gene expression research reagents, fluorescent proteins, genome-editing research reagents, and iPS cell research reagents. These products are marketed under the TaKaRa, Clontech, and Cellartis brand names. In addition to its product offerings, Takara Bio provides contract services for regenerative medicine products, including the manufacturing of viral vectors and gene-transduced cells, quality and safety testing, and cell banking. The company also offers contract services for gene analysis and testing, such as sequencing, intestinal flora analysis, comprehensive analysis of cancer-associated genes, and cell line creation through genome editing. Takara Bio is actively involved in developing platform technology for biologics development, particularly in gene therapy, aiming to advance therapeutic solutions in this field.
What Products and Services Does TKBIF Offer?
- Develops and sells reagents and instruments for genetic research.
- Offers coronavirus testing kits and related in vitro diagnostics.
- Provides analytical reagents and single-cell analysis systems.
- Manufactures gene expression research reagents and fluorescent proteins.
- Produces genome-editing research reagents and iPS cell research reagents.
- Offers products for stem cell culturing and induction of differentiation.
- Provides contract services for regenerative medicine product manufacturing.
- Offers gene analysis and testing services, including sequencing and intestinal flora analysis.
How Does TKBIF Make Money?
- Sells reagents and instruments to research institutions and pharmaceutical companies.
- Provides contract development and manufacturing organization (CDMO) services for regenerative medicine products.
- Offers gene analysis and testing services to healthcare providers and research organizations.
- Develops and licenses platform technology for biologics development in gene therapy.
What Industry Does TKBIF Operate In?
Takara Bio Inc. operates within the biotechnology industry, which is characterized by rapid innovation, increasing demand for personalized medicine, and growing investment in research and development. Takara Bio competes with other biotechnology companies such as ARHCF (Aridis Pharmaceuticals Inc), ASPHF (Asperitas Pharma), BIESF (BioSig Technologies Inc), DUTV (Dutalys), and GALNF (Galectin Therapeutics Inc). The company's focus on regenerative medicine and gene therapy positions it to capitalize on the growing demand for these advanced therapies.
Who Are TKBIF's Key Customers?
- Research institutions conducting genetic and biological studies.
- Pharmaceutical companies developing and manufacturing regenerative medicine products.
- Healthcare providers offering gene analysis and testing services.
- Biotechnology companies seeking CDMO services for biologics development.
Company Profile
Takara Bio Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Kusatsu, JP. The company is led by CEO Tsuyoshi Miyamura. TKBIF has traded publicly since 2020.
Key Financial Metrics
Return on equity for Takara Bio Inc. stands at -9.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -7.2%, showing how much profit it generates from its asset base. Its free cash flow yield is -6.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 5.76 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -7.0%, the inverse of the P/E and a quick read on earnings relative to price.
TKBIF Valuation & Market Position
With a $879M market cap, Takara Bio Inc. sits in the small-cap segment of the market. Relative to its peer group, TKBIF's quantitative score of 46/100 is below the peer average of 60/100.
Quarterly Financial Performance: Takara Bio Inc.
Revenue for Takara Bio Inc. came in at $75.1M during Q1 2026, a 22.6% improvement versus the preceding quarter. The company recorded net income of $126K, with diluted EPS of $0.00. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, TKBIF averaged $-0.13 in diluted EPS.
Earnings Track Record
Takara Bio Inc. has missed Wall Street's EPS estimate in 6 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 23.5% below estimates on average.
Forward Outlook
Wall Street analysts project Takara Bio Inc. revenue of about $268.2M for fiscal 2027, with EPS near $0.06.
TKBIF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's strategic direction and future growth.
- Community sentiment has shifted positively, with increased discussions around Takara's innovative bioproducts.
- Recent partnerships with research institutions have bolstered credibility and expanded market reach.
- The ongoing advancements in gene therapy and regenerative medicine align with Takara's core offerings, attracting interest from investors.
Bear Case
- Concerns over regulatory hurdles in the biotech sector could pose challenges for product approvals.
- Market sentiment remains cautious due to macroeconomic uncertainties affecting funding for biotech firms.
- Some community members express skepticism about the sustainability of recent growth trends and profitability.
- Recent earnings reports have highlighted ongoing operational challenges that may hinder short-term performance.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $75M | $125,960 | $0.0010 |
| Q4 2025 | $61M | -$17M | -$0.14 |
| Q3 2025 | $64M | -$37M | -$0.30 |
| Q2 2025 | $64M | -$10M | -$0.09 |
Based on FMP financials and quantitative analysis
TKBIF Latest News
No recent news available for TKBIF.
TKBIF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for TKBIF.
Price Targets
Wall Street price target analysis for TKBIF.
TKBIF MoonshotScore
What does this score mean?
The MoonshotScore rates TKBIF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Tsuyoshi Miyamura
Unknown
Information about Tsuyoshi Miyamura's background is not available in the provided context. His career history, education, and previous roles are unknown. Further research would be needed to provide a comprehensive profile.
Track Record: Information about Tsuyoshi Miyamura's track record is not available in the provided context. Key achievements, strategic decisions, and company milestones under his leadership are unknown. Further research would be needed to assess his performance as CEO.
TKBIF OTC Market Information
The OTC Other tier represents the lowest tier of over-the-counter (OTC) markets. Unlike stocks listed on major exchanges like the NYSE or NASDAQ, companies on the OTC Other tier often have limited financial disclosure, minimal listing requirements, and may not meet the standards for higher-tiered OTCQX or OTCQB markets. This tier typically includes companies with limited operating history, penny stocks, and those facing financial distress. Investing in OTC Other stocks carries significantly higher risks compared to exchange-listed securities due to the lack of regulatory oversight and transparency.
- OTC Tier: OTC Other
- Limited Financial Disclosure: Lack of transparency due to minimal financial reporting requirements.
- Low Liquidity: Difficulty in buying or selling shares due to low trading volumes.
- Price Volatility: Susceptibility to significant price fluctuations due to limited trading activity.
- Regulatory Oversight: Reduced regulatory scrutiny compared to exchange-listed companies.
- Potential for Fraud: Higher risk of fraudulent activities due to less stringent listing requirements.
- Verify the company's registration and legal status.
- Obtain and review any available financial statements.
- Assess the company's management team and their experience.
- Research the company's business model and competitive landscape.
- Evaluate the company's regulatory compliance and risk factors.
- Monitor trading volume and price activity.
- Consult with a financial advisor before investing.
- Subsidiary of Takara Holdings Inc.: Being a subsidiary of a larger, established company provides some level of credibility.
- Operations in Multiple Countries: Global operations suggest a degree of business activity and market presence.
- Focus on Gene Therapy and Regenerative Medicine: Participation in innovative and growing fields within biotechnology.
Common Questions About TKBIF (Healthcare)
What does the AI Score mean for TKBIF?
TKBIF holds an AI Score of 46/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Takara Bio Inc. operates in the bioindustry, CDMO, and gene therapy sectors, providing reagents, instruments, and contract services globally. The company focuses on regenerative medicine and gene …
What does Takara Bio Inc. do?
Takara Bio Inc. operates as a biotechnology company with a focus on bioindustry, contract development and manufacturing organization (CDMO), and gene therapy businesses. It develops, manufactures, and distributes a range of products, including reagents, instruments, and testing kits for genetic research and coronavirus detection.
What are the main risks for TKBIF?
Takara Bio Inc. faces several risks, including intense competition in the biotechnology industry, regulatory changes and compliance requirements in the healthcare sector, and economic downturns that could impact research funding and demand for its products and services. The company's negative P/E ratio and profit margin also pose financial risks.
What are the key factors to evaluate for TKBIF?
Takara Bio Inc. (TKBIF) holds an AI score of 46/100 (low). presents a mixed investment case. The company's strong presence in the regenerative medicine and gene therapy sectors, coupled with its CDMO capabilities, positions it to capitalize on the growing demand for these services. Not financial advice.
How frequently does TKBIF data refresh on this page?
TKBIF's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven TKBIF's recent stock price performance?
Takara Bio Inc. (TKBIF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong presence in the regenerative medicine and gene therapy sectors. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider TKBIF overvalued or undervalued right now?
Takara Bio Inc. (TKBIF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research TKBIF before investing?
Before investing in Takara Bio Inc. (TKBIF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding TKBIF to a portfolio?
Key strength of Takara Bio Inc. (TKBIF): Strong presence in the regenerative medicine and gene therapy sectors. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- AI analysis is pending for TKBIF, which may provide additional insights.